Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C0251013 - PF-06823859 in Active CLE or SLE With Cutaneous Manifestations
2023-503343-33-00Phase 2Completed
- Sponsor
- Pfizer
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial in cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) comparing PF-06823859 with Placebo (2 arms). Primary endpoint: Change from baseline in type 1 interferon gene signature score in lesional skin at Week 12. Started Dec 2023; status: completed.
02
Drugs
dazukibart
03
Conditions
cutaneous lupus erythematosus (CLE)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2023-503343-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503343-33-00.